Product logins

Find logins to all Clarivate products below.


chevron_left

Protein degraders enabling precision interventions for “undruggable” targets

Companies to Watch 2025

Protein degraders are redefining what’s possible in precision medicine. By harnessing the cell’s own machinery to eliminate disease-driving proteins, this therapeutic class is unlocking new treatment opportunities across oncology, autoimmune, inflammatory, and neurodegenerative diseases.

The momentum is clear:

  • Nearly $13bn in deals signed in 2024, with billion-dollar partnerships continuing in 2025
  • Over 35 new clinical trials since 2021, with late-stage programs from Arvinas, Pfizer, BMS, and Genentech
  • The U.S. and China lead global innovation, driving the majority of recent patent activity

But the opportunity extends beyond today’s PROTACs and molecular glues. Our report explores next-generation strategies including degrader-antibody conjugates (DACs), lysosome-targeting chimeras (LYTACs) and autophagy-targeting degraders (AUTACs), that promise to overcome challenges of selectivity, stability, and oral bioavailability.

What’s inside the report?

  • Deal intelligence: Who’s partnering, investing, and shaping the deal landscape
  • Clinical milestones: The most advanced assets, including Arvinas/Pfizer’s vepdegestrant (ARV-471), which reduced disease progression or death by 43% vs fulvestrant in phase 3 and is now under FDA review
  • Company profiles: Emerging biotechs to watch, including Beactica, Nurix, Kymera, Monte Rosa, and TRIANA, each leveraging proprietary discovery platforms to target the undruggable
  • Global trends: Where innovation is happening, from Boston to Basel to Beijing
  • Regulatory outlook: How agencies are approaching this new modality and what it means for approval pathways

This Companies to Watch report was built using proprietary data and insights from the Clarivate Cortellis suite — including Clinical Trials Intelligence Competitive Intelligence Deals Intelligence Drug Discovery Intelligence , and OFF-X safety intelligence . Combined, they deliver a thorough understanding of scientific developments, market dynamics, and potential investment or partnership opportunities in protein degrader therapies.

 

Related insights

The latest news, technologies, and resources from our team.

Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Drug combinations: your questions answered Drug combinations: your questions answered
Blog November 19, 2024
Drug combinations: your questions answered
These six radioligand therapy companies to watch are ushering in a new era of precision oncology These six radioligand therapy companies to watch are ushering in a new era of precision oncology
Blog June 18, 2025
These six radioligand therapy companies to watch are ushering in a new era of precision oncology
chevron_left
chevron_right